Neoadjuvant systemic treatment strategies have improved outcomes in several solid tumour types. This success has not yet been replicated in renal cell carcinoma (RCC). A consensus and international collaboration are urgently needed for the development of adaptive perioperative immunotherapy strategies for patients with RCC at high risk of recurrence.
European urology. 2025 Jan 23 [Epub ahead of print]
Axel Bex, Michael Jewett, Bryan Lewis, E Jason Abel, Laurence Albiges, Stephanie A Berg, Gennady Bratslavsky, David Braun, James Brugarolas, Toni K Choueiri, Antonio Finelli, Daniel George, Naomi B Haas, A Ari Hakimi, Hans Hammers, Michelle Hirsch, Eric Jonasch, Payal Kapur, W Marston Linehan, Viraj Master, Bradley McGregor, Rana R McKay, Rohit Mehra, Sumantha Pal, Susan Poteat, Thomas B Powles, Sabrina H Rossi, Daniel D Shapiro, Sabina Signoretti, Eric A Singer, Chuck Stravin, Nizar Tannir, Ulka Vaishampayan, Wenxin Xu, Grant D Stewart
Division of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust, University College London, London, UK. Electronic address: ., Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., KidneyCAN, Philadelphia, PA, USA., Departments of Urology and Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA., Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, TX, USA; Department of Internal Medicine (Hematology-Oncology), UT Southwestern Medical Center, Dallas, TX, USA., Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA., Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Department of Internal Medicine (Hematology-Oncology), UT Southwestern Medical Center, Dallas, TX, USA., Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA., Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA., Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., University of California-San Diego, La Jolla, CA., Department of Pathology, Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Barts Cancer Institute and the Royal Free NHS Trust, Queen Mary University, London, UK., Department of Surgery, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Centre, Cambridge Biomedical Campus, Cambridge, UK., Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Division of Urologic Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Patient advocate, Quincy, MA, USA., Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.